Advertisement

Topics

New Turkish Biosimilar Insulin Glargine Poses Challenge For Sanofi’s Lantus

21:28 EDT 1 Sep 2017 | SCRIP

Koçak Farma’s launch of a biosimilar version of Lantus could encourage Sanofi to invest in local production in Turkey, especially...

      

Related Stories

 

Original Article: New Turkish Biosimilar Insulin Glargine Poses Challenge For Sanofi’s Lantus

NEXT ARTICLE

More From BioPortfolio on "New Turkish Biosimilar Insulin Glargine Poses Challenge For Sanofi’s Lantus"

Quick Search
Advertisement
 

Relevant Topics

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Sanofi-Aventis
Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world. Although Sanofi-Aventis products are for a a very wide range of health problems, their major products are those for diabetes, o...